Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion
Therapies using mesenchymal stromal cells (MSCs) to treat immune and inflammatory
conditions are now at an exciting stage of development, with many MSC-based products
progressing to phase II and III clinical trials. However, a major bottleneck in the clinical
translation of allogeneic MSC therapies is the variable immunomodulatory properties of
MSC products due to differences in their tissue source, donor heterogeneity and processes
involved in manufacturing and banking. This variable functionality of MSC products likely …
conditions are now at an exciting stage of development, with many MSC-based products
progressing to phase II and III clinical trials. However, a major bottleneck in the clinical
translation of allogeneic MSC therapies is the variable immunomodulatory properties of
MSC products due to differences in their tissue source, donor heterogeneity and processes
involved in manufacturing and banking. This variable functionality of MSC products likely …
以上显示的是最相近的搜索结果。 查看全部搜索结果